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Background: KIT is a proto-oncogene involved in diverse neoplastic processes. Aberrant kinase activity of the KIT
receptor has been targeted by tyrosine kinase inhibitor (TKI) therapy in different neoplasias. In all the earlier studies,
KIT expression was reported to be absent in meningiomas. However, we observed KIT mRNA expression in some
meningioma cases. This prompted us to undertake its detailed analyses in meningioma tissues resected during
2008–2009.
Methods: Tumor tissues and matched peripheral blood samples collected from meningioma patients were used
for detailed molecular analyses. KIT expression was ascertained immunohistochemically and validated by
immunoblotting. KIT and KITLG transcript levels were discerned by reverse transcription quantitative real-time PCR
(RT-qPCR). Similarly, KIT amplification and allele loss were assessed by quantitative real-time (qPCR) and validated by
fluorescence in situ hybridization (FISH) on the neoplastic tissues. Possible alterations of the gene at the nucleotide
level were analyzed by sequencing.
Results: Contrary to earlier reports, KIT expression, was detected immunohistochemically in 20.6% meningioma
cases (n = 34). Receptor (KIT) and ligand (KITLG) transcripts monitored by RT-qPCR were found to co-express
(p = 0.048) in most of the KIT immunopositive tumors. 1/7 KIT positive meningiomas showed allele loss
corroborated by reduced FISH signal in the corresponding neoplastic tissue. Sequence analysis of KIT showed
M541L substitution in exon 10, in one of the immunopositive cases. However, its biological consequence remains
to be uncovered.
Conclusions: This study clearly demonstrates KIT over-expression in the human meningiomas. The data suggest
that up-regulated KIT transcription (p< 0.001), instead of gene amplification (p> 0.05), is a likely mechanism
responsible for altered KIT expression. Thus, KIT is a potential candidate for detailed investigation in the context of
meningioma pathogenesis.Background
Genetic alterations causing deregulated expression of
oncogenes and tumor suppressor genes underlie most of
the neoplastic events. Receptor tyrosine kinases (RTKs)
constitute a discrete category of oncogenes and are inte-
gral molecules of signaling cascades. Their aberrations
and deranged cross-talks lead to pathological conditions
[1]. KIT (CD117, SCFR) a proto-oncogene on human
chromosome 4q12, encodes one such transmembrane
RTK of type III receptor family [2,3]. Its pleiotropic at-
tribute is well established as the gene is involved in* Correspondence: alisher@nii.ac.in
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reproduction in any medium, provided the ornormal growth and developmental processes [4-7].
KITLG (KIT Ligand/SCF-12q22) is the ligand of KIT re-
ceptor [8]. In the normal human adult, a striking re-
gional expression pattern for KIT and KITLG is seen in
the central nervous system (CNS). Normal meninges are
KIT and KITLG immunonegative with interspersed KIT
positive mast cells [9]. KIT stimulation by KITLG also
triggers oncogenic signaling pathways resulting in unre-
stricted proliferation, cell survival, migration and apop-
tosis [10]. Hypoxia in the tumor microenvironment
induces KITLG secretion furthering neovascularisation
and promoting tumor sustenance [11].
Aberrant KIT expression is reported in gastrointestinal
stromal tumors (GISTs), acute myeloid leukemia (AML),
small cell lung carcinoma, breast cancer, gliomas andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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expression showed mRNA levels ranging from 0.01 to
5.8 folds, based on RT-qPCR [13]. In GISTs, oncogenic
activation of KIT is the frequent pathogenic mechanism
and hence its expression serves as a diagnostic bio-
marker. KIT positive cases, bearing its activating muta-
tions show a spectacular response to inhibition therapy
with imatinib [14]. Imatinib mesylate (STI-571) or
GleevecW is a selective TKI developed to target ABL
(Abelson kinase) in BCR-ABL fusion oncoprotein in
CML patients. It was fortuitously found to inhibit other
kinases such as PDGFR (alpha- and beta-platelet-derived
growth factor receptors) and KIT, in GISTs and other
malignancies [15]. In view of the above, evaluation of
the KIT for its role in tumors of the CNS seems to be
a clinically rewarding proposition.
Meningiomas are mesenchymal tumors originating
from the meninges. Based on the degrees of malig-
nancy, these tumors are graded as benign (WHO grade
I), atypical (WHO grade II) and anaplastic/malignant
(WHO grade III) [16]. Overall, meningiomas are neo-
plasms where the benign forms exert their devastating
effects through volume expansion in confined regions
of the brain. Besides producing increased intracranial
pressure, the malignant forms are associated with brain
invasion, early recurrence and decreased survival rates.
At times, their location in the brain is critical, such
that they press upon important faculties and show ten-
acity even to surgical intervention [17]. In view of this,
alternate therapeutic approaches are being explored to
address these challenges.
Meningiomas have been reported to lack KIT expres-
sion in three independent studies [18-20]. Of these, one
on KIT expression in germinomas randomly included a
single meningioma sample [19]. In the second one on
human solid tumors, 8 meningioma cases were included
[18]. The third study focused on the analysis of KIT
immunoexpression in 37 meningiomas and reported lack
of its expression [20]. Clinical trials were undertaken
with imatinib singly or in combination with hydroxyurea,
in recurrent meningiomas [21,22]. These trials were
based on the reports that implicated co-expression of
PDGF and PDGFR in autocrine growth stimulation of
meningioma cells. One of the trials was closed prema-
turely due to slow accrual. Further, due to insufficient
number of samples available for validating PDGFR ex-
pression, its correlation with imatinib treatment could
not be established [21]. The second trial reported the
combination therapy to have modest anti-tumor activity
[22]. The biopsies of patients enrolled in these trials were
not profiled for possible KIT expression/alterations.
Despite reported absence of KIT expression in men-
ingiomas, our initial observation of its mRNA expression
(by RT-PCR) in some cases (Additional file 1A) evokedour interest to ascertain its status in the present study.
We indeed observed up-regulated KIT protein and
mRNA expression in a subset of meningiomas.
Methods
Sample collection
The protocols followed in the present study were
approved by both, the National Institute of Immunol-
ogy’s Institutional Human Ethics Committee and the
Max Healthcare Ethics Committee. A series of 34
patients operated consecutively for primary intracranial
meningiomas during May 2008-August 2009 at the
Max hospital’s Neurosciences department was included
in this study. Parts of the resected tumor tissues and
matched peripheral blood samples were collected from
meningioma patients with their written informed con-
sents. The samples were taken at the first diagnosis of
meningioma without further selection. Histopathological
examination and grading of tumors were performed fol-
lowing WHO guidelines 2007 [16]. Of the 34 meningi-
oma (M) samples collected, 24 were from females and
10, males. Case M29 was diagnosed with multiple men-
ingiomas (right frontal and cervical), but the intracra-
nial right frontal one was surgically resected and
analyzed in this study. Tables 1 and 2 summarize the
grade wise distribution of the cases analyzed in the
present study and details of KIT immunopositive men-
ingioma cases, respectively.Isolation of genomic DNA, total RNA and cDNA synthesis
DNA extraction kit (Qiagen, Valencia, CA, USA) was
used to isolate DNA from peripheral blood leukocytes
(PBLs) as per the manufacturer’s protocol. Tumor tissue
portions collected in RNAlater (Ambion, Austin, TX,
USA), were used for DNA isolation by phenol chloro-
form extraction method, following standard protocol
[23]. Total RNA isolation from tumor tissues was per-
formed using Tri Reagent RT (Molecular Research
Centre, Cincinnati, OH, USA), as recommended by the
manufacturer. Quality of isolated DNA and RNA was
evaluated using 1% agarose and 1% denaturing agarose
gels, respectively. Concentration and purity of the nu-
cleic acids were confirmed using the spectrophotometer.
Potential DNA contamination of total RNA was checked
using GAPDH primers in a 20 μl reaction volume of
PCR. Subsequently, RNA was reverse transcribed using
High Capacity cDNA Archive kit (ABI, Carlsbad, CA,
USA). PCR was conducted using ACTB primers for
assessing the quality of synthesized cDNA (Additional
file 1B). Primers for the cytoplasmic domain of KIT were
used to detect the gene’s transcripts in the samples by
RT-PCR (Additional file 1A). Primer details have been
given in Additional file 2.
Table 1 Grade wise distribution of meningioma cases analyzed
Meningiomas Grade I (Varaint/Sub-type) Grade II Grade III Total
Ag X Mg Fb T At Ap
Cases analyzed 1 1 15 6 7 3 1 34
KIT positive cases – – 2 (13.3%) 1 (16.7%) 3 (42.9%) 1 (33.3%) – 7 (20.6%)
(Ag, Angiomatous; At, Atypical; Ap, Anaplastic; Fb, Fibroblastic; Mg, Meningothelial; T, Transitional; X, Xanthomatous).
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Serial sections of formalin fixed paraffin embedded
(FFPE) tumor tissues used for histopathological diagnosis
were evaluated for KIT expression using immunoperoxi-
dase-diaminobenzidine (HRP-DAB) staining. Differences
in KIT expression in other types of cancers have been
attributed to properties of the antibody and staining pro-
cedure used for IHC. Therefore, in the present study
anti-human KIT antibody from DAKO (A4502), reported
to have higher sensitivity was used [24,25]. Briefly, 4 μm
thin sections were de-waxed, washed through graded
ethanol series and rehydrated under running water. The
staining was performed by careful optimization of the
vendor’s recommendations. Heat induced epitope re-
trieval (HIER, previously optimized) was performed in
boiling 1:0.1 mM Tris-EDTA buffer pH 9.0 in a pressure
cooker for ~3 minutes (Pattern of KIT staining without
HIER was also found to be similar in our hands).
Tumoral tissue sections (TTS) were treated with perox-
idase block (3% H2O2) for 15 minutes. Samples were then
sequentially incubated with polyclonal rabbit anti-human
KIT antibody (A4502, DAKO, Carpinteria, CA, USA,
optimized dilution 1:100) for 60 minutes, DAKO EnVi-
sion + System-HRP labelled polymer for 30 minutes and
DAKO liquid DAB+ substrate chromogen system for 10
minutes, in a humid chamber at room temperature.Table 2 Clinico-pathological and KIT-IHC details of the immun
Details
M10






Details of KIT-IHC analyses % positivity a 4
Staining intensity b W
Stain localization c C
Staining pattern c D,G
(Clinical data: Ml, Male; Fl, Female. Ag, Angiomatous; At, Atypical; Ap, Anaplastic; F
Left occipital; LP, Left Parietal; LPP, Left parietal parasaggital; PS, Planum sphenoida
Experimental data: a 0 = 0%, 1 += 1–10%, 2 += 11–50%, 3 += 51–75%, 4 +=≥ 75.
b W, Weak (+); Md, Moderate (++); S, Strong (+++).
c C, Cytoplasmic; D, Diffuse; F, Focal; G, Granular; H, Homogeneous.Following each incubation step, TTS were rinsed in
1xTBS (pH 7.6) thrice for 2 minutes. They were counter
stained in Harris haematoxylin for 2 minutes, dehydrated
in an ethanol series, air-dried and mounted in DPX. To
ensure specificity of the antibody, appropriate controls,
such as uterine tissue (negative control), GIST (charac-
terized KIT positive case) from the clinical collaborators
and commercially purchased normal meningeal tissue
sections (BioChain, Hayward, CA, USA) were included
for processing in each batch. Additionally, a negative
control omitting the primary antibody was included. The
TTS were evaluated for staining using light microscopy,
by two pathologists to account for inter-observer vari-
ability. The pathologists were unaware of the genetic
analyses. Immuno-stained tissues were imaged on 1X51
microscope (Olympus, Tokyo, Japan) equipped with
U-CMAD 3 camera (Olympus) operated by DP Con-
troller software v3.1.1267 (Olympus) and Image Pro
Express 6.3 software (Media Cybernetics, MD, USA).
Presence of KIT immunostain was evaluated for cri-
teria such as, percentage positivity (0 = 0%, 1 + = 5–10%,
2 + = 11–50%, 3 + = 51–75%, 4 + = ≥ 75%), location (cyto-
plasmic, nuclear, fibrillar), pattern (diffuse, focal, granu-
lar, homogeneous) and intensity (weak; +, moderate; ++,
strong; +++). To ensure reproducibility of results, IHC
was repeated twice for the KIT positive cases.opositive meningioma cases
Meningioma Cases
M14 M15 M16 M21 M29 M37
48 59 32 51 44 49
Fl Fl Fl Fl Fl Fl
I I I I II I
T Mg T Fb At T
LPP PS FM LP RF LO
– – – – – –
2 2-4 1 4 3 1
Md W-Md W S S W
C C C C C C
F,G H,G H,G D D F,G
b, Fibroblastic; Mg, Meningothelial; T, Transitional; FM, Foramen magnum; LO,
le; RF, Right frontal; RSW, Right sphenoid wing.
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Cases, where adequate tumor tissues were available, the
IHC findings were confirmed by western blotting. For
this, tumor tissues were lysed in RIPA lysis buffer and
separated by centrifugation. Commercially purchased
total proteins of relevant non-neoplastic tissues were
used as controls (Biochain). After resolving the proteins
on 12% SDS polyacrylamide gels, they were transferred
onto nitrocellulose membranes (Millipore, Billercia, MA,
USA). The membranes were blocked in PBS buffer sup-
plemented with 3% non-fat dried milk and 2% BSA (Cell
Signaling Technology, Boston, MA, USA). Membranes
were probed using polyclonal rabbit anti-human KIT
(A4502, DAKO, dilution 1:1500) and polyclonal rabbit
anti-Beta Tubulin (RB-9249-P1; Neo Markers, Thermo
Fisher Scientific, Fremont, CA, USA, dilution 1:10,000)
as primary antibodies. The proteins were detected using
horse-radish peroxidase conjugated goat anti-rabbit anti-
body (111-036-045, Jackson Immuno Research Labora-
tories Inc., West Grove, PA, USA, dilution 1:10,000) and
immobilon western chemiluminescent HRP substrate
(Millipore).
Real-time quantification of KIT and KITLG transcripts
Primers for the genes of interest (GI) and reference (GR)
were designed using Primer Express 3.0 software (ABI).
Specificity of the primers was confirmed by blastn algo-
rithm of the BLAST program. GAPDH was used as an
endogenous control or GR, as it showed stable expres-
sion in both control and test samples. SYBRW green
(ABI) assays were performed for relative quantification of
KIT and KITLG transcripts on 7500 Real-Time PCR Sys-
tem (ABI). Commercially purchased total RNA of human
♂ meninges and ♀ dura were used as controls or calibra-
tors (BioChain and Clontech, Mountain View, CA, USA;
respectively). Two fold dilution series of the cDNA tem-
plate were assayed to generate standard and disassoci-
ation curves. Standard curves of primers, for all the three
genes, had slope values within the range of −3.3 to −3.4,
R2 >0.99 (co-efficient of determination) confirming com-
parable PCR efficiencies and good fit of data points, re-
spectively. Further single melting curve peaks validated
specific amplification (data not shown). Standard curve
was employed to ascertain the amount of sample cDNA
to be used for RT-qPCR. All the assays were performed
using respective gene’s 100 nM of forward and reverse
primers, in a final reaction volume of 20 μl. Universal
cycling conditions as recommended by ABI were
employed to amplify GIs and GR in separate wells. The
results were ratified, when of the triplicate Ct values
(Cycle threshold), at least two were concordant. Expres-
sion levels were calculated by the relative quantification
(RQ= 2−ΔΔCt) method [26]. ΔΔCt is the cycle threshold
normalized first with the endogenous control (ΔCt =CtGI - Ct GR) and then with the calibrator sample (ΔΔCt =
ΔCt Sample - ΔCt Calibrator). SDS 7500™ Software
v2.0.3 was used to analyze the data and heat map was
generated using Data Assist™ Software v2.0 (ABI).Copy number assessment of KIT by qPCR
Copy number of KIT was assessed using a commercial
pre-designed TaqManW assay (Hs02812715_cn; ABI) and
RNase P as the reference gene (TaqManW RNase P de-
tection kit P/N: 4316831, ABI) on 7500 Real-Time PCR
System (ABI). Tumor DNA comprised the test samples.
DNA from matched PBLs of respective patients was also
assayed, as endogenous genetic complement to ascertain
whether copy number variations are de novo neoplastic
events. Commercially purchased human brain DNA
(BioChain), two genomic DNA samples (provided with
the RNase P detection kit, ABI) and blood DNA from 2
healthy volunteers served as controls. Universal cycling
conditions recommended by ABI were used to amplify
all samples and controls in triplicates. The reactions
were set up as 20 μl singleplex assays, using 20 ng of
genomic DNA, 1x TaqManW Universal PCR Master Mix
(ABI) and 1x primer probe mix (ABI). A normal sample
theoretically has two copies of KIT/diploid genome.
Therefore, gene copy number per diploid genome was
calculated using the equation 2 x (2−ΔΔCt) [26]. During
the study, all the possible measures were taken to avoid
non-neoplastic DNA contribution to the test samples.
To substantiate the qPCR findings and to rule out ex-
perimental errors resulting from potential non-neoplas-
tic cell contribution, FISH was performed on FFPE
tissue sections of KIT immunopositive cases.Fluorescence in situ hybridization
Dual-colour FISH was performed to evaluate KIT status
and Chromosome 4 ploidy. For this purpose, 4 μm thin
serial sections were used from the FFPE tissue blocks,
employed earlier for diagnosis and KIT IHC. Moreover,
FISH was conducted on primary tumor specimens, in-
stead of cultured tumor cells, to rule out any genetic
alterations brought about by in vitro manipulation.
Commercially purchased normal brain cerebellar tissue
section (BioChain) was used as control. Pre-treatment of
TTS was performed as described earlier [27]. Subse-
quently, co-hybridization was conducted using bacterial
artificial chromosome (BAC) clone; RP11-586A2 (KIT-
4q12; BACPAC Resource CHORI, Oakland, CA, USA)
and spectrum green-labelled Chromosome 4 enumer-
ation probe (CEPW4, Vysis, Il, USA) as per manufac-
turer’s specifications. The BAC clone was nick translated
with Texas Red-12-dUTP (Invitrogen, Carlsbad, CA,
USA). After hybridization, the nuclei were counter-
stained with DAPI (Vector Labs, Burlingame, CA, USA).
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pus) and approximately 200 non-overlapping tumor-cell
nuclei were evaluated from each case. U-TV1X-2 cam-
era fitted on the microscope and CytoVisionTM and
GenusTM imaging softwares (Applied Imaging, CA,
USA) were used to capture the images. A KIT/nucleus
signal ratio of ≥ 2.5 or KIT/CEP4 signal ratio of ≥ 1.5
was considered as KIT copy number gain. To confirm
the identity of the BAC (RP11-686A2), used for FISH,
the clone was streaked to obtain single colonies on LB
agar with recommended antibiotics. Of these single col-
onies, 5 were randomly screened by PCR (Additional
file 3) and sequenced (data not shown) using primers
specific for portions of each domain of KIT.
Genomic sequence analysis of KIT exons
Based on relevant literature review, KIT exons were
selected for mutational screening. PCR was performed
with 50 ng of tumor and matched blood DNA as tem-
plate from the KIT positive cases in a reaction volume
of 35 μl, using primers specific for exons 1, 9, 10, 11,
12, 13 and 17 of KIT. Commercially purchased human
brain (BioChain) and blood DNA from a healthy volun-
teer were used as controls. The amplicons were electro-
phoresed on a 1% agarose gel and purified using
QIAquick gel extraction kit as per manufacturer’s guide-
lines (Qiagen). Sequencing (2X) was conducted with
these purified PCR fragments as templates using Big
DyeW Terminator v3.1 chemistry (ABI) and standard
protocol, on 3130xl Genetic Analyser (ABI). Sequences
were screened for mutations and compared with corre-
sponding human reference KIT exon sequence at NCBI,
using Sequence Analysis software v5.3.1 and SeqScapeW
software v2.6 (ABI).
Statistical analysis
Sigma Plot 11.0 (Systat Software Inc., Germany) was used
to analyze frequency tables employing χ2 test or Fisher’s
exact test. Microsoft Excel 2007 was used to generate
scatter plots. The Pearson product–moment correlation
coefficient (r), p values and significance of correlation of
the plots were determined using Sigma Plot 11.0.
Results
KIT immunoexpression is detected in the neoplastic
meninges
KIT immunopositivity was detected in 20.6% (7/34)
meningioma cases (Table 1, Figure 1C-G) as opposed to
the earlier report of its negligible expression in 37 men-
ingioma cases [20]. The details of KIT staining intensity,
pattern, localization and percentages of immunopositive
cells are given in Table 2. Moderate (++) KIT staining
was seen in 2/7 meningioma cases, while, strong (+++)
expression was detected in 2/7 cases.Specificity and sensitivity of the anti-KIT antibody and
efficacy of the staining protocol were confirmed by the
relevant staining patterns observed in the characterized
KIT positive and negative control tissues. GIST showed
a promisingly strong KIT immunostaining in the cyto-
plasm with foci of membranous staining (Figure 1A,
black arrow). The uterine tissue was indeed KIT negative
and presented a clear background (IHC staining not
shown). Further, interspersed KIT positive mast cells in
an otherwise KIT negative meningioma served as an
internal control (Figure 1B). The western blot results
were in accordance with that of the IHC observations
(Figure 1H). The two immunoassays conducted in the
present study used the common antibody to detect
KIT, thereby verifying its sensitivity.
KIT and KITLG mRNA are co-up regulated in the
immunopositive meningiomas
In the present study, heat maps were generated using
Euclidean distance and complete linkage to hierarchic-
ally cluster meningioma cases based on ΔCt values of
KIT and KITLG expression (Figure 2A, for ΔCt calcula-
tion see methods). ΔCt values below and above the
mean value indicate up-(red) and down-regulation
(blue), respectively (ΔCt scale insert in Figure 2A).
KIT immunopositivity was significantly associated with
up-regulated transcript levels in meningioma (p< 0.001
for pair wise comparison, Figure 2C). In the immunopo-
sitive meningiomas with up-regulated KIT transcripts,
RQ values were found to be in the range of 1.13 to 2.92
(for RQ calculations, see methods). Further, KITLG tran-
scripts showed significant co-expression with its recep-
tor in immunopositive cases (p = 0.048, Figure 2B). Up-
regulated KITLG expression showed RQ values ranging
from 1.05 to 5.19 in the KIT immunoreactive cases.
A possible correlation of FISH and qPCR amplification
To determine whether an increase in the KIT copy num-
ber contributes to its over-expression, we undertook its
quantification studies. Interestingly, of the 7 KIT positive
meningiomas, none showed copy number gain of this
gene. Similar observations of KIT over-expression with-
out gain in the gene’s copy number have been reported
in GISTs and paediatric renal tumors [13,28]. Notably,
M29 tumor tissue showed copy number value of 1.2
(Figure 3B) and 95% of the cells showing KIT/nucleus
fluorescence signal ratio of ≤ 1.4, suggesting loss of KIT
allele, akin to hemizygosity s (Additional file 4). This
corroborated with a single fluorescing signal for KIT
(red) in the interphase nuclei (Figure 3A). Observed loss
of KIT allele in the corresponding case primarily repre-
sented neoplastic event since the matched blood sample
was found to have 2 copies of KIT (Figure 3B, Additional
file 4). All the other cases, except the one discussed here
Figure 1 Immunoexpression of KIT in meningioma and control samples. (A-G) Immunohistochemical staining results (A) GIST (positive
control) showing strong immunopositivity with membranous staining (black arrow), (B) an otherwise KIT negative meningioma showing
interspersed positive mast cells (red arrows) representing an internal control, (C) meningothelial meningioma (M10) showing weak granular
cytoplasmic staining, (D) transitional meningioma (M14) displaying moderate focal staining, (E) a meningothelial meningioma (M15) with weak to
moderate cytoplasmic KIT staining, (F) fibroblastic meningioma (M21) showing strong staining of the cytoplasm, (G) an atypical meningioma
(M29) with strong cytoplasmic KIT expression. (H) Immunoblots of neoplastic and non-neoplastic (NN) tissue lysates, probed with antibodies to
KIT and β-Tubulin.
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constitutional counterparts. KIT expression (RQ) plotted
against the gene’s copy number showed no significant
correlation between the two parameters (p> 0.05,
Figure 3C).Sequencing of KIT shows nucleotide variation in a single
immunoreactive case
Analysis of KIT in the immunopositive meningioma
cases did not reveal loss or gain of function mutations
as reported in other pathological conditions. Particu-
larly, though 1/7 meningioma KIT positive cases
showed a transversion (A!C) in exon 10, leading to a
mis-sense substitution, (Met!Leu) at codon 541
(M541L) (Figures 4B and 5, Additional file 4). The vari-
ant is an acknowledged reference SNP, rs3822214 in the
SNP database dbSNP 135 and is also reported by the
Catalogue Of Somatic Mutations in Cancer database
(COSMIC) as COSM28026 [29,30]. Figure 4A representsthe normal allele pattern as seen in the genomic DNA of
non-neoplastic brain and control PBLs.
The variant was observed along with the normal allelic
nucleotide in the electropherograms of tumor tissue and
matched blood sample of the corresponding patient (Fig-
ure 4B, Additional file 4). Therefore, it can be construed
that the variation has been stably inherited and is not a
de novo neoplastic aberration. This SNP having minor
allele frequency has been reported by other groups, how-
ever its clinical significance is unknown [30].
Discussion
Contrary to earlier reports of absence of KIT expression
in meningiomas, the present study showed its expression
in 20.6% cases [18-20]. Of these studies, the one on
human solid tumors analyzed only 8 meningioma sam-
ples using the DAKO antibody we used in the present
study but the staining protocol was not described in suf-
ficient details [18]. The second study was conducted on
germinomas using the same antibody and similar
Figure 2 RT-qPCR estimation of KIT and KITLG in immunopositive and negative tumor cases. (A) Heat map demonstrating hierarchical
clustering of meningioma cases based on ΔCt values. Red asterisk indicates KIT immunopositive cases; representative KIT negative cases are also
shown. Scatter plots showing extent of correlation between (B) KITLG and KIT mRNA expression, and (C) intensity of KIT staining and its relative
transcript expression in immunopositive meningioma cases, respectively.
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study. However, only one meningioma sample was
examined [19]. The third study systematically evaluated
KIT expression in 37 meningiomas employing a similar
staining protocol but a different anti-KIT antibody
(MBL, Nagoya, Japan) [20]. Therefore, it is difficult to at-
tribute specific reason(s) to the observed deviation or to
compare present study with the earlier ones.Figure 3 Copy number status of KIT and its correlation with expressio
sequences on chromosome 4 (green) on tissue sections (100x). M37 and n
KIT copy number. (B) qPCR based KIT copy number results of meningioma
plot showing relative expression of KIT Vs its copy number in immunopositWe selected the anti-KIT antibody (DAKO) over
other commercial antibodies based on its wide spread
usage by different groups working on closely related
fields [25,31-36]. Nevertheless, wide variations are prac-
tised with regard to antigen retrieval methods and
reagents used; and therefore a consensus staining
protocol is yet to be established. Employing HIER,
the DAKO antibody showed reduced KIT staining inn. (A) dual-colour FISH showing KIT signal (red) and centromeric
on-neoplastic cerebellum (control) show normal, M29 shows decreased
cases; whose FISH micrographs have been shown in (A). (C) scatter
ive meningioma cases.
Figure 4 Electropherograms displaying mutation screening of KIT exon 10. (A) Expected reference allele pattern (green arrows) in DNA
from PBL and normal brain “A” (green peak) at first position of codon 541 (exon 10). (B) Heterozygous allele pattern (red arrows) showing
substitution in DNA from KIT positive tumor and matched blood sample in M16. PBL refers to peripheral blood leukocytes, T signifies tumor tissue.
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remained unaffected with or without antigen retrieval
[25,35]. Further, there are conflicting reports about ef-
fect of antigen retrieval on KIT staining observed in
desmoids tumors [25,35,36]. Therefore, in absence of
a standard protocol, especially for meningiomas, the
vendor’s specifications were followed with careful
optimization in the present study. It is noteworthy
that the relevant controls showed appropriate staining
patterns and the KIT staining results were substan-
tiated by immunoblotting using the same anti-KIT
antibody (DAKO).
Graded co-expression of KIT and Zonulin (marker for
degraded blood brain barrier) in different grades of brain
tumors (5 GBMs and one case each of astrocytoma
WHO III and meningioma WHO III) was reported earl-
ier [37]. A meningioma WHO I used as control lacked
KIT expression but showed some Zonulin expression.
Further, by co-staining Zonulin with a marker for blood
vessels (GSI), it was demonstrated that the blood brainbarrier was degraded in meningioma WHO III unlike
meningioma WHO I. The current finding on the single
meningioma grade III being KIT negative reflects a
chance occurrence. Use of additional grade III tumor
samples for KIT expression analyses would fully resolve
this issue.
KIT and/or KITLG expression quantification in men-
ingiomas was not performed thus far. To the best of
our knowledge, data regarding KIT/KITLG expression
in the context of meningioma cell lines is not available
in public expression database (Array Express on EMBL-
EBI). Reportedly, endogenous KITLG co-expression
leads to activation of KIT receptors in glioma cell lines
and other cancers [38-40]. In the present study, quanti-
fication of KIT and KITLG transcripts revealed signifi-
cant co-expression in the immunoreactive cases
(Figures 2B and 5). Further, with no discernible activat-
ing KIT mutations in immunopositive meningioma
cases, the receptor could possibly get activated via auto-
crine and/or paracrine modes in these tumors.
Figure 5 Summary of KIT analyses in the immunopositive meningiomas.
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immunoexpression and elevated KIT transcript levels
(Figures 2C and 5). Incidentally, correlation between pro-
tein and mRNA expression levels was not always corrob-
orative as in the cases of M10 and 37 (Figure 5). It needs
to be determined whether genetic, post-transcriptional or
translational mechanisms; regulated in turn by molecules
governing KIT expression, underlie these observations.
Similar discordance between expression of gene at the
transcript and protein levels has been reported earlier
[41]. Interestingly, case M29, despite loss of KIT allele
in the tumor tissue showed strong immunostaining
and 1.61 fold higher levels of its transcript (Figure 5,
Additional file 4). This could be due to: i) altered
pre-transcriptional regulation, ii) some unascertained
post-transcriptional modification(s) or mutation(s) in
the mRNA and/or iii) post-translational modification(s)
in the protein leading to their respective stabilization.
M541L substitution observed in the transmembrane
domain in a solitary meningioma case (M16) has also
been reported amongst healthy individuals [42,43]. This
substitution was shown to be non-activating in vitro,
though this observation may not fully reconcile with an
in vivo scenario [44].
Taken together, it would be of interest to pursue
whether the enhanced KIT expression in subset of men-
ingioma cases acts as a catalyst in, complicit to or as a
consequence of the meningeal neoplastic process. Fur-
ther, it would be vital to determine whether KIT immu-
nopositive meningioma cases, indeed have an activated
oncoprotein. Owing to insufficient quantum of resected
tissues, this aspect could not be pursued during the
present study. Also, due to varying incidence rates of
meningioma grades/sub-types, patient accrual andsample collection are slow processes. These limitations
pose impediment for a study on fair distribution of all
the pathologic subtypes.
Conclusions
Conclusively, contrary to earlier reports, present study de-
monstrates KIT immunoexpression in a subset of human
meningiomas. The data suggest that over-expression of
the receptor in meningioma occurs without gene amplifi-
cation and is associated with transcriptional activation.
Continued work in this area would help elucidate the
relative contribution of deranged KIT expression to
the oncogenic pathways operative in this neoplasia, thus
facilitating optimization of treatment modalities.
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Additional file 1 Figure S1. Detection of KIT transcripts by RT-PCR. (A)
RT-PCR results of representative meningioma tumor tissues using primers
specific to cytoplasmic domain of the KIT. (B) Confirmation of the quality
of cDNA synthesis through RT-PCR using ACTB primers (also served as
well loading control). Note the absence of amplicons in the no template
control (NTC). NN denotes non-neoplastic. (TIFF 183 kb)
Additional file 2 Table S2. Details of the primers used. (DOC 51 kb)
Additional file 3 Figure S2. Agarose gel pictures verifying identity of
the BAC clone RP11-586A2. PCR amplification for establishing the identity
of BAC clone using primers specific to: (A) cytoplasmic; (B)
transmembrane and (C) extracellular domains of the KIT. Note the
absence of amplification in the no template control (NTC). The
characterized clones were used to determine alterations of KIT in the
neoplastic tissue by FISH. C denotes colony and NN, non-neoplastic. (TIFF
266 kb)
Additional file 4 Table S2. Copy number status of KIT, its signal
intensity based on FISH and mutation analysis. (DOC 47 kb)
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